Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.53 |
| ▸ | HCAR2 | Q8TDS4 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | TDO2 | P48775 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | KCNK3 | O14649 | 2/20 | 0.39 |
| ▸ | KCNK9 | Q9NPC2 | 2/20 | 0.39 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | AR | P10275 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21678774 | 0.84 | SMN1; SMN2 (0.50) | KDM4EHSD17B10MAPTHPGDALDH1A1 | |
| Fumaric Acid SCHEMBL28397774 | 0.83 | IRAK4 (0.60) | IRAK4HCAR2KDM4EHSD17B10MAPT | |
| SCHEMBL27958806 | 0.83 | IRAK4 (0.68) | IRAK4KDM4EHSD17B10HPGDIDO1 | |
| SCHEMBL240024 | 0.82 | HSD17B10 (0.65) | HCAR2KDM4EHSD17B10MAPTHPGD | |
| SCHEMBL33469 | 0.81 | HCAR2 (0.50) | HCAR2KDM4EHSD17B10MAPTHPGD | |
| SCHEMBL21678701 | 0.80 | HCRTR1 (0.49) | HCAR2KDM4EHSD17B10MAPTHPGD | |
| SCHEMBL4332049 | 0.80 | IRAK4 (0.64) | IRAK4KDM4EHSD17B10HPGDIDO1 | |
| SCHEMBL27568908 | 0.79 | IRAK4 (0.58) | IRAK4KDM4EHSD17B10MAPTIDO1 | |
| SCHEMBL21678752 | 0.78 | KMT2A (0.47) | HCAR2KDM4EHSD17B10MAPTHPGD | |
| SCHEMBL28026162 | 0.77 | IRAK4 (0.60) | IRAK4KDM4EHSD17B10HPGDIDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11866401-B2 | Salicyl fumarate derivative and its application in the treatment of Parkinson's disease and other neurodegenerative diseases | CHONGQING NEUROPARK BIOSCIENCE CO., LTD. (CN) | 2024-01-09 | — | — | US | disclosed |
| US-20210179533-A1 | SALICYL FUMARATE DERIVATIVE AND ITS APPLICATION IN THE TREATMENT OF PARKINSON'S DISEASE AND OTHER NEURODEGENERATIVE DISEASES | CHONGQING NEUROPARK BIOSCIENCE CO., LTD. (CN) | 2021-06-17 | — | — | US | disclosed |
| EP-3611157-A1 | SALICYLIC ACID-BASED FUMARATE DERIVATIVE AND USE IN TREATMENT OF PARKINSON'S DISEASE AND OTHER NEURODEGENERATIVE DISEASES | Chongqing Neuropark Bioscience Co., Ltd. (CN) | 2020-02-19 | — | — | EP | disclosed |
| US-20200048182-A1 | A SALICYL FUMARATE DERIVATIVE AND ITS APPLICATION IN THE TREATMENT OF PARKINSON'S DISEASE AND OTHER NEURODEGENERATIVE DISEASES | CHONGQING NEUROPARK BIOSCIENCE CO., LTD. (CN) | 2020-02-13 | — | — | US | disclosed |
| CN-106946701-A | Salicylic acid-based fumarate derivative and application thereof in treating Parkinson's disease and other neurodegenerative diseases | 杨立川 | 2017-07-14 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210179533-A1 | SALICYL FUMARATE DERIVATIVE AND ITS APPLICATION IN THE TREATMENT OF PARKINSON'S DISEASE AND OTHER NEURODEGENERATIVE DISEASES | FH, SUCNR1, SDHB | IRAK4 482/4885HCAR2 61/4885KDM4E 2864/4885 |
| US-20200048182-A1 | A SALICYL FUMARATE DERIVATIVE AND ITS APPLICATION IN THE TREATMENT OF PARKINSON'S DISEASE AND OTHER NEURODEGENERATIVE DISEASES | FH, SUCNR1, SDHB | IRAK4 448/4885HCAR2 75/4885KDM4E 2634/4885 |
| US-11866401-B2 | Salicyl fumarate derivative and its application in the treatment of Parkinson's disease and other neurodegenerative diseases | FH, SUCNR1, SDHB | IRAK4 532/4885HCAR2 88/4885KDM4E 2757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.